Ieq Capital LLC Buys 5,171 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Ieq Capital LLC boosted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 307.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,852 shares of the biotechnology company’s stock after purchasing an additional 5,171 shares during the period. Ieq Capital LLC’s holdings in United Therapeutics were worth $2,418,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Creative Planning lifted its holdings in shares of United Therapeutics by 8.9% during the 3rd quarter. Creative Planning now owns 3,935 shares of the biotechnology company’s stock valued at $1,410,000 after buying an additional 322 shares during the period. Raymond James & Associates lifted its holdings in United Therapeutics by 1.7% in the third quarter. Raymond James & Associates now owns 35,751 shares of the biotechnology company’s stock valued at $12,811,000 after acquiring an additional 609 shares during the period. Sequoia Financial Advisors LLC boosted its position in United Therapeutics by 12.6% in the third quarter. Sequoia Financial Advisors LLC now owns 723 shares of the biotechnology company’s stock worth $259,000 after purchasing an additional 81 shares during the last quarter. Signaturefd LLC grew its stake in shares of United Therapeutics by 8.8% during the 3rd quarter. Signaturefd LLC now owns 633 shares of the biotechnology company’s stock valued at $227,000 after purchasing an additional 51 shares during the period. Finally, International Assets Investment Management LLC increased its position in shares of United Therapeutics by 140,617.1% during the 3rd quarter. International Assets Investment Management LLC now owns 57,694 shares of the biotechnology company’s stock valued at $20,675,000 after purchasing an additional 57,653 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In related news, Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the sale, the director now directly owns 5,051 shares in the company, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $896,950.62. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 114,164 shares of company stock worth $41,671,293 in the last 90 days. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Performance

UTHR stock opened at $361.10 on Monday. The company has a market capitalization of $16.12 billion, a PE ratio of 15.86, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. The company’s fifty day moving average price is $362.68 and its 200-day moving average price is $360.72. United Therapeutics Co. has a one year low of $214.75 and a one year high of $417.82.

Analyst Ratings Changes

A number of research firms recently issued reports on UTHR. Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH boosted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. The Goldman Sachs Group boosted their price target on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. Finally, UBS Group raised their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.